“ARCA started because there was a heartbreaking need for new drugs to treat HIV,” says Melanie Thompson, M.D. “The landscape for HIV research has indeed changed, largely as a result of our successes.”
Tonia Poteat, Ph.D., PA-C, M.P.H., and Marlon M. Bailey, Ph.D., dive into the important takeaways of a major new report on sexual and gender diverse populations in the U.S.
The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.
W. David Hardy, M.D., discusses the takeaway messages for HIV care providers after a recent research paper found that a third of all people living with HIV reported never discussing U=U with their provider.
With Several Curative Therapies for Hepatitis C on the Market, the Research Pipeline for Prevention Continues
The authors of an influential annual report on hepatitis C research and development talk through what's new and evolving in clinical science.
A Vaginal Ring to Prevent HIV Was Given a Positive Opinion by a European Drug Regulator. Here’s What You Need to Know About It.
Two experts discuss the history of the ring, how it works, and when it may come to the United States.
This researcher has some ideas about what we need to do to address the problem.
As With HIV, New York State Was Set to Lead the Nation to End Hepatitis C. But Why Haven’t the Recommendations Been Made Public?
Activist and member of the state task force Annette Gaudino would like the public to know.
Descovy’s approval for PrEP showcases real-life ramifications of leaving trans people out of research. But including trans people is about more than just saying trans people are welcome, says researcher Brian Minalga.
“I’m not a physician. … We can diagnose and treat, but fundamentally we are taught to care.”